Cg Oncology, Inc. (CGON) Stock Price & Analysis
Cg Oncology, Inc. (CGON) fell 2.53% to USD 69.32 as of July 25, 2026 at 02:24 UTC, according to Nexqual real-time market data.
CGON last closed at USD 71.12; the session ranged USD 68.96–71.02 on volume of 351,318 shares. Market capitalization is $6.11B, with a 52-week range of USD 23.65–77 (NMS). Source: Nexqual, July 25, 2026 at 02:24 UTC.
Key Statistics (as of July 25, 2026 at 02:24 UTC)
| Price | USD 69.32 |
|---|---|
| Change | ▼ 2.53% (down) |
| Previous Close | USD 71.12 |
| Open | USD 71.02 |
| Day Range | USD 68.96 – 71.02 |
| 52-Week Range | USD 23.65 – 77 |
| Volume | 351,318 shares |
| Market Cap | $6.11B |
| Exchange | NMS |
Technical Analysis (CGON)
Nexqual's technical model rates CGON "NEUTRAL" based on 3 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 02:24 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 54.69 (neutral) |
| vs SMA50 | Above (USD 65.56) |
| MACD | 1.31 (positive) |
Analyst Ratings (CGON)
Wall Street analysts rate CGON "Strong Buy" based on 13 analysts, with a mean price target of USD 90.69 (range USD 80–108), per Nexqual as of July 25, 2026 at 02:24 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 90.69 |
| High Target | USD 108 |
| Low Target | USD 80 |
| Buy / Hold / Sell | 14 / 1 / 0 |
Earnings (CGON)
| Next Earnings Date | 2026-08-07 |
|---|---|
| EPS Estimate | USD -0.64 |
| Revenue Estimate | $362,640 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.71 vs est -0.54 ▼ miss |
| 2025-12-31 | USD -0.51 vs est -0.58 ▲ beat |
| 2025-09-30 | USD -0.57 vs est -0.55 ▼ miss |
| 2025-06-30 | USD -0.54 vs est -0.45 ▼ miss |
Source: Nexqual, July 25, 2026 at 02:24 UTC.
Financials & Fundamentals (CGON)
| Total Revenue | $5.07M |
|---|---|
| Revenue Growth (YoY) | +1982.70% |
| Gross Margin | +0.00% |
| Operating Margin | -6130.10% |
| Profit Margin | +0.00% |
| ROE | -20.79% |
| Debt / Equity | 0.69 |
| Current Ratio | 31.3 |
| Total Cash | $1.08B |
| Total Debt | $7.58M |
| Free Cash Flow | $-105.89M |
Source: Nexqual, July 25, 2026 at 02:24 UTC.
Financial Health Score (CGON)
Nexqual rates Cg Oncology, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 02:24 UTC.
| Growth | Strong — Revenue +255% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $1.08B cash vs $8M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$106M, burning cash |
| Efficiency | Critical — ROE -21%, ROA -14.4% |
Ownership (CGON)
| Insider Ownership | +0.23% |
|---|---|
| Institutional Ownership | +109.65% |
| Shares Outstanding | 88.20M |
| Float | 65.82M |
| Short % of Float | +13.93% |
Source: Nexqual, July 25, 2026 at 02:24 UTC.
Leadership (CGON)
Cg Oncology, Inc. is led by Arthur Kuan (age 34), President, Chairman & CEO, per Nexqual as of July 25, 2026 at 02:24 UTC.
| President, Chairman & CEO | Arthur Kuan (age 34) |
|---|---|
| Chief Financial Officer | James M. DeTore (age 60) |
| Vice President of Finance & Administration | Amy Steele |
| Vice President of Communications & Patient Advocacy | Sarah Connors |
| Vice President of Corporate Development | Bing Kung |
Major Backers & Investors (CGON)
Notable institutional backers of Cg Oncology, Inc. include T. Rowe Price, RTW Investments LP, Decheng Capital LLC, according to Nexqual as of July 25, 2026 at 02:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| T. Rowe Price | 11.8% |
| RTW Investments LP | 7.92% |
| Decheng Capital LLC | 7.22% |
| Wellington Management | 6.09% |
| FMR, LLC | 4.27% |
| TCG Crossover Management, LLC | 4.16% |
| Price (T.Rowe) Associates Inc | 4.14% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 16.18% |
| BlackRock | 7.34% |
| State Street | 2.05% |
Source: Nexqual, July 25, 2026 at 02:24 UTC.
From Cg Oncology, Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
- It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| APGE | Apogee Therapeutics, Inc. | USD 134.28 | ▲ 0.15% |
| AVBP | ArriVent BioPharma, Inc. | USD 31.73 | ▲ 4.24% |
| SYRE | Spyre Therapeutics, Inc. | USD 102.13 | ▲ 2.98% |
| MLYS | Mineralys Therapeutics, Inc. | USD 26.71 | ▼ 1.11% |
| EWTX | Edgewise Therapeutics, Inc. | USD 40.84 | ▲ 6.55% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 02:24 UTC. This page is informational and not investment advice.